(Reuters) - Cytori Therapeutics Inc said it has suspended enrollments in two trials of its experimental cell therapy for heart failure patients after a safety review.
The company's shares fell 13 percent in extended trade.
Cerebrovascular events - those related to blood vessels in the brain - were reported in studies to evaluate safety and feasibility of adipose-derived regenerative cells in patients with ischemic heart disease, the company said.
Symptoms occurred in three patients, the company said. Two patients' symptoms fully resolved within a short period, it said, while the third has experienced a substantial resolution.
Cytori's shares closed at $2.10 on the Nasdaq on Tuesday.
(Reporting by Shailesh Kuber; Editing by Ted Kerr)